Muscular dystrophy: Experimental animal models and therapeutic approaches (Review)

被引:8
作者
Gaina, Gisela [1 ,2 ]
Popa , Alexandra [1 ,3 ]
机构
[1] Victor Babes Natl Inst Pathol, Lab Cell Biol Neurosci & Expt Myol, Splaiul Independentei 99-101, Bucharest 050096, Romania
[2] Univ Bucharest, Dept Biochem & Mol Biol, Bucharest 050095, Romania
[3] Univ Agron Sci & Vet Med Bucharest, Dept Anim Prod & Publ Hlth, Bucharest 050097, Romania
关键词
muscular dystrophy; animal models; gene therapy; mdx mouse; canine model; pig model; read-through; exon skipping; MDX MOUSE MODEL; GLYCOPROTEIN COMPLEX; MUSCLE FUNCTION; MOLECULAR-BASIS; GENE-THERAPY; DUCHENNE; EXPRESSION; MICE; UTROPHIN; SKELETAL;
D O I
10.3892/etm.2021.10042
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The muscular dystrophies are a heterogeneous group of genetically inherited diseases characterized by muscle weakness and progressive wasting, which can cause premature death in severe forms. Although >30 years have passed since the identification of the first protein involved in a type of muscular dystrophy, there is no effective treatment for these disabling disorders. In the last decade, several novel therapeutic approaches have been developed and investigated as promising therapeutic approaches aimed to ameliorate the dystrophic phenotype either by restoring dystrophin expression or by compensating for dystrophin deficiency. Concurrently, with the development of therapeutic approaches, in addition to naturally occurring animal models, a wide range of genetically engineered animal models has been generated. The use of animals as models of muscular dystrophies has greatly improved the understanding of the pathogenicity of these diseases and has proven useful in gene therapy studies. In this review, we summarize these latest innovative therapeutic approaches to muscular dystrophies and the usefulness of the various most common experimental animal models.
引用
收藏
页数:9
相关论文
共 116 条
  • [71] Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD
    McClorey, G.
    Moulton, H. M.
    Iversen, P. L.
    Fletcher, S.
    Wilton, S. D.
    [J]. GENE THERAPY, 2006, 13 (19) : 1373 - 1381
  • [72] Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy
    McGreevy, Joe W.
    Hakim, Chady H.
    McIntosh, Mark A.
    Duan, Dongsheng
    [J]. DISEASE MODELS & MECHANISMS, 2015, 8 (03) : 195 - 213
  • [73] Muscle diseases: The muscular dystrophies
    McNally, Elizabeth M.
    Pytel, Peter
    [J]. ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE, 2007, 2 : 87 - 109
  • [74] Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member
    McPherron, AC
    Lawler, AM
    Lee, SJ
    [J]. NATURE, 1997, 387 (6628) : 83 - 90
  • [75] MEIER H., 1958, CORNELL VET, V48, P313
  • [76] Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy
    Moretti, A.
    Fonteyne, L.
    Giesert, F.
    Hoppmann, P.
    Meier, A. B.
    Bozoglu, T.
    Baehr, A.
    Schneider, C. M.
    Sinnecker, D.
    Klett, K.
    Froehlich, T.
    Rahman, F. Abdel
    Haufe, T.
    Sun, S.
    Jurisch, V.
    Kessler, B.
    Hinkel, R.
    Dirschinger, R.
    Martens, E.
    Jilek, C.
    Graf, A.
    Krebs, S.
    Santamaria, G.
    Kurome, M.
    Zakhartchenko, V.
    Campbell, B.
    Voelse, K.
    Wolf, A.
    Ziegler, T.
    Reichert, S.
    Lee, S.
    Flenkenthaler, F.
    Dorn, T.
    Jeremias, I.
    Blum, H.
    Dendorfer, A.
    Schnieke, A.
    Krause, S.
    Walter, M. C.
    Klymiuk, N.
    Laugwitz, K. L.
    Wolf, E.
    Wurst, W.
    Kupatt, C.
    [J]. NATURE MEDICINE, 2020, 26 (02) : 207 - +
  • [77] Use of Animal Models of Human Disease for Nonclinical Safety Assessment of Novel Pharmaceuticals
    Morgan, Sherry J.
    Elangbam, Chandikumar S.
    Berens, Shawn
    Janovitz, Evan
    Vitsky, Allison
    Zabka, Tanja
    Conour, Laura
    [J]. TOXICOLOGIC PATHOLOGY, 2013, 41 (03) : 508 - 518
  • [78] Role of telomere dysfunction in cardiac failure in Duchenne muscular dystrophy
    Mourkioti, Foteini
    Kustan, Jackie
    Kraft, Peggy
    Day, John W.
    Zhao, Ming-Ming
    Kost-Alimova, Maria
    Protopopov, Alexei
    DePinho, Ronald A.
    Bernstein, Daniel
    Meeker, Alan K.
    Blau, Helen M.
    [J]. NATURE CELL BIOLOGY, 2013, 15 (08) : 895 - U300
  • [79] Dystrophin and mutations: one gene, several proteins, multiple phenotypes
    Muntoni, F
    Torelli, S
    Ferlini, A
    [J]. LANCET NEUROLOGY, 2003, 2 (12) : 731 - 740
  • [80] Clinical potential of ataluren in the treatment of Duchenne muscular dystrophy
    Namgoong, John Hyun
    Bertoni, Carmen
    [J]. DEGENERATIVE NEUROLOGICAL AND NEUROMUSCULAR DISEASE, 2016, 6 : 37 - 48